David L. Rimm MD, PhD, from Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
David L. Rimm MD, PhD, Professor of Pathology and of Medicine (Medical Oncology), Director of Pathology Tissue Services, Director of Translational Pathology, Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
<<<
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More